Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Liquidia Technologies IncLQDA · Entity 145051 | President and CFO | February 22, 2019 | February 23, 2019 |
| Progyny, Inc.PGNY · Entity 4521 | Director | September 10, 2026 | September 18, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 08, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Liquidia Technologies Inc
Report date February 22, 2019 · Filed February 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,915 |
Reported balance
After 2019-02-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-02-22 · Sale · Disposed 293 · Balance 162,915 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.52 to $16.21, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. F3: Includes (i) 2,364 former restricted stock units ("RSUs") which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 293 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; F4: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. |
| Common StockSEC Table I · non-derivative | Direct | 162,703 |
Reported balance
After 2019-02-22 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-02-22 · Sale · Disposed 212 · Balance 162,703 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F5: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.82 to $16.84, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5 to this Form 4. F6: Includes (i) 2,152 former RSUs which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 505 shares of common stock (inclusive of the 293 shares which were sold as described in footnotes 3 and 4) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; F7: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. |
| Common StockSEC Table I · non-derivative | Direct | 162,265 |
Reported balance
After 2019-02-22 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2019-02-22 · Sale · Disposed 438 · Balance 162,265 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F8: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.25, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 8 to this Form 4. F9: Includes (i) 1,714 former RSUs which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 943 shares of common stock (inclusive of the 293 shares which were sold as described in footnotes 3 and 4 and the 212 shares which were sold as described in footnotes 6 and 7) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; F10: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018.
F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.52 to $16.21, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
F3: Includes (i) 2,364 former restricted stock units ("RSUs") which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 293 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date;
F4: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date.
F5: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.82 to $16.84, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5 to this Form 4.
F6: Includes (i) 2,152 former RSUs which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 505 shares of common stock (inclusive of the 293 shares which were sold as described in footnotes 3 and 4) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date;
F7: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date.
F8: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.25, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 8 to this Form 4.
F9: Includes (i) 1,714 former RSUs which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 943 shares of common stock (inclusive of the 293 shares which were sold as described in footnotes 3 and 4 and the 212 shares which were sold as described in footnotes 6 and 7) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date;
F10: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date.
Progyny, Inc.
Report date September 10, 2026 · Filed September 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,792 |
Last balance in matching sequence
After 2026-09-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-09-10 · Exercise / conversion · Acquired 22,000 · Balance 28,792 Row 2 · 2026-09-10 · Tax withholding · Disposed 10,500 · Balance 18,292 Row 3 · 2026-09-10 · Sale · Disposed 11,500 · Balance 6,792 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2: This Form 4 is being filed to correct a clerical error in a previously filed Form 4. The weighted average for the transaction was inadvertently reported as $27.9442 instead of $27.1181. All other information previously reported remains unchanged. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2029-10-11 | Direct | 22,000 |
Reported balance
After 2026-09-10 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2026-09-10 · Exercise / conversion · Disposed 22,000 · Balance 22,000 F3: The shares are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F2: This Form 4 is being filed to correct a clerical error in a previously filed Form 4. The weighted average for the transaction was inadvertently reported as $27.9442 instead of $27.1181. All other information previously reported remains unchanged.
F3: The shares are fully vested.
VERACYTE, INC.
Report date June 08, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,720 |
Ending reported balance
After 2022-06-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-08 · Exercise / conversion · Acquired 15,000 · Balance 23,720 Row 2 · 2022-06-08 · Sale · Disposed 15,000 · Balance 8,720 F1: Represents weighted average sales price. Sale prices for the transactions range from $18.00 to $18.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2026-12-11 | Direct | 0 |
Reported balance
After 2022-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-08 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents weighted average sales price. Sale prices for the transactions range from $18.00 to $18.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F2: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 18, 2026 22:46 UTC Amendment | Progyny, Inc. PGNY · Entity 4521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001551306-26-000154 · wk-form4a_1789771587.xml · derivative · entry 4 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares are fully vested. Read SEC document |
| September 10, 2026 Filed Sep 18, 2026 22:46 UTC Amendment | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 11,500 | $27.12 | $311,858.15 |
DisclosureSEC source: 0001551306-26-000154 · wk-form4a_1789771587.xml · nonDerivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,792 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 · price: This Form 4 is being filed to correct a clerical error in a previously filed Form 4. The weighted average for the transaction was inadvertently reported as $27.9442 instead of $27.1181. All other information previously reported remains unchanged. Read SEC document |
| September 10, 2026 Filed Sep 18, 2026 22:46 UTC Amendment | Progyny, Inc. PGNY · Entity 4521 | Tax withholdingCommon Stock | 10,500 | $27.24 | $286,020.00 |
DisclosureSEC source: 0001551306-26-000154 · wk-form4a_1789771587.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,292 Read SEC document |
| September 10, 2026 Filed Sep 18, 2026 22:46 UTC Amendment | Progyny, Inc. PGNY · Entity 4521 | Exercise / conversionCommon Stock | 22,000 | $13.00 | $286,000.00 |
DisclosureSEC source: 0001551306-26-000154 · wk-form4a_1789771587.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 21:53 UTC | Progyny, Inc. PGNY · Entity 4521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001551306-26-000152 · wk-form4_1789422827.xml · derivative · entry 4 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares are fully vested. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 21:53 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 11,500 | $27.94 | $321,358.30 |
DisclosureSEC source: 0001551306-26-000152 · wk-form4_1789422827.xml · nonDerivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,792 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 21:53 UTC | Progyny, Inc. PGNY · Entity 4521 | Tax withholdingCommon Stock | 10,500 | $27.24 | $286,020.00 |
DisclosureSEC source: 0001551306-26-000152 · wk-form4_1789422827.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,292 Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 21:53 UTC | Progyny, Inc. PGNY · Entity 4521 | Exercise / conversionCommon Stock | 22,000 | $13.00 | $286,000.00 |
DisclosureSEC source: 0001551306-26-000152 · wk-form4_1789422827.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:16 UTC | Progyny, Inc. PGNY · Entity 4521 | OtherCommon Stock | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-26-000112 · wk-form4_1780085776.xml · nonDerivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,027 F2 · price: Shares were transferred from the reporting person individually. F3 · ownership.nature: The reportable securities are held directly by the Kevin Gordon Revocable Declaration of Trust U/A/D 9/3/2013. The Reporting Person serves as trustee of the trust. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:16 UTC | Progyny, Inc. PGNY · Entity 4521 | OtherCommon Stock | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-26-000112 · wk-form4_1780085776.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,792 F1 · price: Shares were transferred to the Kevin Gordon Revocable Declaration of Trust U/A/D 9/3/2013. The reporting person serves as trustee of the trust. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:16 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,500 | $24.99 | $137,445.00 |
DisclosureSEC source: 0001551306-26-000112 · wk-form4_1780085776.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,318 Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:23 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 30,373 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001551306-26-000103 · wk-form4_1779827032.xml · derivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,373 Underlying: Common Stock · 30,373 shares Expires 2036-05-20 F3 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:23 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 6,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-26-000103 · wk-form4_1779827032.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,818 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 22:12 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,500 | $22.04 | $55,087.50 |
DisclosureSEC source: 0001551306-25-000169 · wk-form4_1755123168.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 12,501 F1 · balance_after: Includes an increase of 5,147 shares which were transferred to the Kevin Gordan Revocable Declaration of Trust U/A/D 9/3/2013 (the "Trust") on June 2, 2025 from shares that were previously reported as directly held by the Reporting Person. The Reporting Person serves as trustee of the Trust. F2 · ownership.nature: The reportable securities are directly held by the Kevin Gordon Revocable Declaration of Trust U/A/D 9/3/2013. The Reporting Person serves as trustee of the trust. Read SEC document |
| May 22, 2025 Filed May 28, 2025 01:56 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.89 | $0.00 |
DisclosureSEC source: 0001551306-25-000122 · wk-form4_1748397357.xml · derivative · entry 4 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 6,600 shares Expires 2035-05-21 F4 · derivative.exercise_date: The shares subject to the option will vest 25% on the first anniversary of the grant date, with the remainder vesting in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service on each applicable vesting date. Read SEC document |
| May 22, 2025 Filed May 28, 2025 01:56 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 34,049 | $0.00 Strike: $20.89 | $0.00 |
DisclosureSEC source: 0001551306-25-000122 · wk-form4_1748397357.xml · derivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,049 Underlying: Common Stock · 34,049 shares Expires 2035-05-21 F3 · derivative.exercise_date: The shares subject to the option will vest on May 22, 2026, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 22, 2025 Filed May 28, 2025 01:56 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 8,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-25-000122 · wk-form4_1748397357.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,173 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 22, 2026, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:54 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 23,212 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001551306-24-000124 · wk-form4_1716947637.xml · derivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,212 Underlying: Common Stock · 23,212 shares Expires 2034-05-22 F3 · derivative.exercise_date: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:54 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 5,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-24-000124 · wk-form4_1716947637.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,801 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 00:06 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,500 | $35.93 | $89,825.00 |
DisclosureSEC source: 0001551306-23-000112 · wk-form4_1702512382.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,854 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.90 to $35.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 16,990 | $0.00 Strike: $38.24 | $0.00 |
DisclosureSEC source: 0001628280-23-019976 · wf-form4_168513495759773.xml · derivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,990 Underlying: Common Stock · 16,990 shares Expires 2033-05-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,410 | $38.24 | $53,918.40 |
DisclosureSEC source: 0001628280-23-019976 · wf-form4_168513495759773.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,354 Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 3,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-019976 · wf-form4_168513495759773.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,764 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $38.22 | $0.00 |
DisclosureSEC source: 0001628280-22-027088 · wf-form4_166681821969793.xml · derivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2032-10-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027088 · wf-form4_166681821969793.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 23, 2023 subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001384101-22-000080 · wf-form4_165489392090834.xml · derivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 15,000 | $18.50 | $277,501.50 |
DisclosureSEC source: 0001384101-22-000080 · wf-form4_165489392090834.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $18.00 to $18.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 15,000 | $7.39 | $110,850.00 |
DisclosureSEC source: 0001384101-22-000080 · wf-form4_165489392090834.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 21:47 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (right to buy) · Derivative | 14,658 | $0.00 Strike: $63.21 | $0.00 |
DisclosureSEC source: 0001179110-21-009633 · edgar.xml · derivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,658 Underlying: Common Stock · 14,658 shares Expires 2026-10-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on October 24, 2022, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 21:47 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 2,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009633 · edgar.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,210 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on October 24, 2022, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:20 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 8,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000113 · wf-form4_162335639984759.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001437749-21-000133 · rdgdoc.xml · derivative · entry 4 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,523 | $49.27 | $272,134.23 |
DisclosureSEC source: 0001437749-21-000133 · rdgdoc.xml · nonDerivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.04 to $49.56. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,477 | $48.62 | $217,664.13 |
DisclosureSEC source: 0001437749-21-000133 · rdgdoc.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,523 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.02 to $49.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.39 | $73,900.00 |
DisclosureSEC source: 0001437749-21-000133 · rdgdoc.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 22:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001437749-20-023860 · rdgdoc.xml · derivative · entry 4 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on December 12, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 22:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,806 | $47.85 | $86,415.29 |
DisclosureSEC source: 0001437749-20-023860 · rdgdoc.xml · nonDerivative · entry 3 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.56 to $48.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 22:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 8,194 | $46.95 | $384,722.23 |
DisclosureSEC source: 0001437749-20-023860 · rdgdoc.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,806 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $46.50 to $47.48. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 22:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.39 | $73,900.00 |
DisclosureSEC source: 0001437749-20-023860 · rdgdoc.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 1, 2020. Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 21:53 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0001209191-20-055955 · doc4.xml · derivative · entry 2 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-10-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on October 24, 2021, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2020 Filed Oct 27, 2020 21:53 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055955 · doc4.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on October 24, 2021, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:49 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001384101-20-000097 · wf-form4_159173575610370.xml · derivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on June 8, 2021 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 01:51 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054021 · doc4.xml · derivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2029-10-11 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option shall vest on October 24, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001384101-19-000070 · wf-form4_156045800947196.xml · derivative · entry 1 GORDON KEVIN K · CIK 0001218483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option becomes exercisable in full on June 12, 2020 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 02:09 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | SaleCommon Stock | 438 | $18.09 | $7,923.42 |
DisclosureSEC source: 0001104659-19-010159 · a4.xml · nonDerivative · entry 3 GORDON KEVIN K · CIK 0001218483 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,265 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F8 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.25, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 8 to this Form 4. F9 · balance_after: Includes (i) 1,714 former RSUs which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 943 shares of common stock (inclusive of the 293 shares which were sold as described in footnotes 3 and 4 and the 212 shares which were sold as described in footnotes 6 and 7) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; F10 · balance_after: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 02:09 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | SaleCommon Stock | 212 | $16.83 | $3,567.96 |
DisclosureSEC source: 0001104659-19-010159 · a4.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,703 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F5 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.82 to $16.84, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5 to this Form 4. F6 · balance_after: Includes (i) 2,152 former RSUs which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 505 shares of common stock (inclusive of the 293 shares which were sold as described in footnotes 3 and 4) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; F7 · balance_after: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 02:09 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | SaleCommon Stock | 293 | $15.83 | $4,638.19 |
DisclosureSEC source: 0001104659-19-010159 · a4.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,915 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.52 to $16.21, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. F3 · balance_after: Includes (i) 2,364 former restricted stock units ("RSUs") which settled into common stock on February 22, 2019 on a net basis following the sales of an aggregate of 293 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (iii) 93,025 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; F4 · balance_after: (iv) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (v) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:15 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | SaleCommon Stock | 8,355 | $14.84 | $123,988.20 |
DisclosureSEC source: 0001104659-19-003185 · a4.xml · nonDerivative · entry 2 GORDON KEVIN K · CIK 0001218483 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F5 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.39, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5 to this Form 4. F6 · balance_after: Includes (i) 20,572 former RSUs which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 11,322 shares of common stock (inclusive of the 2,967 shares which were sold as described in footnote 3) to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 95,682 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; (iii) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and F7 · balance_after: (iv) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:15 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | SaleCommon Stock | 2,967 | $14.14 | $41,953.38 |
DisclosureSEC source: 0001104659-19-003185 · a4.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,563 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2018. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $14.36, inclusive. The reporting person undertakes to provide to Liquidia Technologies, Inc., any holder of Liquidia Technologies, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. F3 · balance_after: Includes (i) 28,927 former restricted stock units ("RSUs") which settled into common stock on January 22, 2019 on a net basis following the sales of an aggregate of 2,967 shares of common stock to cover estimated taxes, transaction costs and fees associated with the vesting event, (ii) 95,682 remaining RSUs granted on January 22, 2018, which shall be settled into common stock in 36 equal monthly installments commencing January 22, 2019, subject to Mr. Gordon's continuous service as of each such date; (iii) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and F4 · balance_after: (iv) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:06 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantCommon Stock | 5,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-062293 · a4.xml · nonDerivative · entry 1 GORDON KEVIN K · CIK 0001218483 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,530 F1 · balance_after: Includes (i) 127,576 restricted stock units ("RSUs") granted on January 22, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on January 22, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; (ii) 41,084 RSUs granted on July 25, 2018, which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on July 25, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date; and (iii) 5,870 RSUs granted on October 12, 2018 which shall be settled into common stock pursuant to the following vesting schedule: 25% of the RSUs shall vest on August 14, 2019, with the remaining 75% of such RSUs vesting in 36 equal monthly installments thereafter, subject to Mr. Gordon's continuous service as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.